Chapter 19 Metabolic Effects of AEDs. Impact on Body Weight, Lipids and Glucose Metabolism

International Review of Neurobiology

Volumn 83, Issue , 2008, Pages 329-346

  Sheth, Raj D ^a   Montouris, Georgia ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GLUCOSE;

BODY WEIGHT; DRUG EFFECT; EPILEPSY; HUMAN; LIPID METABOLISM; METABOLISM; REVIEW;

ANTICONVULSANTS; BODY WEIGHT; EPILEPSY; GLUCOSE; HUMANS; LIPID METABOLISM;

EID: 53049093165     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(08)00019-6     Document Type: Review

References (64)

1. Acharya J.N., Satishchandra P., and Shankar S.K. Familial progressive myoclonus epilepsy: Clinical and electrophysiologic observations. Epilepsia 36 (1995) 429-434
2. al-Rubeaan K., and Ryan E.A. Phenytoin-induced insulin insensitivity. Diabet. Med. 8 (1991) 968-970
3. Aronne L.J. Classification of obesity and assessment of obesity-related health risks. Obes. Res. 10 Suppl. 2 (2002) 105S-115S
4. Aronne L.J. Obesity as a disease: Etiology, treatment, and management considerations for the obese patient. Obes. Res. 10 Suppl. 2 (2002) 95S-96S
5. Arroyo S., Anhut H., Kugler A.R., Lee C.M., Knapp L.E., Garofalo E.A., and Messmer S. Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45 (2004) 20-27
6. Aydin K., Serdaroglu A., Okuyaz C., Bideci A., and Gucuyener K. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J. Child Neurol. 20 (2005) 848-851
7. Ballaban-Gil K., Callahan C., O'dell C., Pappo M., Moshe S., and Shinnar S. Complications of the ketogenic diet. Epilepsia 39 (1998) 744-748
8. Bell N.H., and Key Jr. L.L. Acquired osteomalacia. Curr. Ther. Endocrinol. Metab. 5 (1994) 495-499
9. Ben-Menachem E., Axelsen M., Johanson E.H., Stagge A., and Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes. Res. 11 (2003) 556-562
10. Biton V. Effect of antiepileptic drugs on bodyweight: Overview and clinical implications for the treatment of epilepsy. CNS Drugs 17 (2003) 781-791
11. Biton V., Mirza W., Montouris G., Vuong A., Hammer A.E., and Barrett P.S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56 (2001) 172-177
12. Boggs J.G. Seizures in medically complex patients. Epilepsia 38 Suppl. 4 (1997) S55-S59
13. Bourgeois B.F. Felbamate. Semin. Pediatr. Neurol. 4 (1997) 3-8
14. Carter B.L., Small R.E., Mandel M.D., and Starkman M.T. Phenytoin-induced hyperglycemia. Am. J. Hosp. Pharm. 38 (1981) 1508-1512
15. Castro-Gago M., Novo-Rodriguez M.I., Blanco-Barca M.O., Urisarri-Ruiz De Cortazar A., Rodriguez-Garcia J., Rodriguez-Segade S., and Eiris-Punal J. Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J. Child Neurol. 21 (2006) 48-53
16. Corman C.L., Leung N.M., and Guberman A.H. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can. J. Neurol. Sci. 24 (1997) 240-244
17. DeLorenzo R.J., Pellock J.M., Towne A.R., and Boggs J.G. Epidemiology of status epilepticus. J. Clin. Neurophysiol. 12 (1995) 316-325
18. DeToledo J.C., Toledo C., Decerce J., and Ramsay R.E. Changes in body weight with chronic, high-dose gabapentin therapy. Ther. Drug Monit. 19 (1997) 394-396
19. Devinsky O., Vuong A., Hammer A., and Barrett P.S. Stable weight during lamotrigine therapy: A review of 32 studies. Neurology 54 (2000) 973-975
20. Dinesen H., Gram L., Andersen T., and Dam M. Weight gain during treatment with valproate. Acta Neurol. Scand. 70 (1984) 65-69
21. Eiris J.M., Lojo S., Del Rio M.C., Novo I., Bravo M., Pavon P., and Castro-Gago M. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 45 (1995) 1155-1157
22. Elinav E., Ackerman Z., Gottehrer N.P., and Heyman S.N. Recurrent life-threatening acidosis induced by acetazolamide in a patient with diabetic type IV renal tubular acidosis. Ann. Emerg. Med. 40 (2002) 259-260
23. Franzoni E., Govoni M., D'addato S., Gualandi S., Sangiorgi Z., Descovich G.C., and Salvioli G.P. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 33 (1992) 932-935
24. Frigerio F., Chaffard G., Berwaer M., and Maechler P. The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate. Biochem. Pharmacol. 72 (2006) 965-973
25. Gidal B.E., Anderson G.W., Spencer N.W., Maly M.M., Murty J., and Collins D.M. Valproate-associated weight gain: Potential relation to energy expenditure and metabolism in patients with epilepsy. J. Epilepsy 9 (1996) 234-241
26. Gidal B.E., Sheth R.D., Magnus L., and Herbeuval A.F. Levetiracetam does not alter body weight: Analysis of randomized, controlled clinical trials. Epilepsy Res. 56 (2003) 121-126
27. Gilliam F., Hecimovic H., and Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav. 4 Suppl. 4 (2003) S26-S30
28. Glauser T.A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 21 (2001) 904-919
29. Greco R., Latini G., Chiarelli F., Iannetti P., and Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65 (2005) 1808-1809
30. Guberman A., and Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 9 (2000) 112-118
31. Ikeda K., Iwasaki Y., Kinoshita M., Yabuki D., Igarashi O., Ichikawa Y., and Satoyoshi E. Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. Intern. Med. 41 (2002) 743-745
32. Inoue T., Kira R., Kaku Y., Ikeda K., Gondo K., and Hara T. Renal tubular acidosis associated with zonisamide therapy. Epilepsia 41 (2000) 1642-1644
33. Isojarvi J.I., Pakarinen A.J., and Myllyla V.V. Serum lipid levels during carbamazepine medication. A prospective study. Arch. Neurol. 50 (1993) 590-593
34. Isojarvi J.I., Rattya J., Myllyla V.V., Knip M., Koivunen R., Pakarinen A.J., Tekay A., and Tapanainen J.S. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. 43 (1998) 446-451
35. Izzedine H., Launay-Vacher V., and Deray G. Topiramate-induced renal tubular acidosis. Am. J. Med. 116 (2004) 281-282
36. Ketter T.A., Post R.M., and Theodore W.H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53 (1999) S53-S67
37. Kossoff E.H., Pyzik P.L., Furth S.L., Hladky H.D., Freeman J.M., and Vining E.P. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 43 (2002) 1168-1171
38. Lothman E. The biochemical basis and pathophysiology of status epilepticus. Neurology 40 Suppl. 2 (1990) 13-23
39. Luef G., Abraham I., Hoppichler F., Trinka E., Unterberger I., Bauer G., and Lechleitner M. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 51 (2002) 1274-1278
40. Luef G.J., Waldmann M., Sturm W., Naser A., Trinka E., Unterberger I., Bauer G., and Lechleitner M. Valproate therapy and nonalcoholic fatty liver disease. Ann. Neurol. 55 (2004) 729-732
41. Mahmoudian T., Iranpour R., and Messri N. Serum lipid levels during carbamazepine therapy in epileptic children. Epilepsy Behav. 6 (2005) 257-259
42. Marquez A.V., Farias S.T., Apperson M., Koopmans S., Jorgensen J., Shatzel A., and Alsaadi T.M. Psychogenic nonepileptic seizures are associated with an increased risk of obesity. Epilepsy Behav. 5 (2004) 88-93
43. Mattson R.H., Cramer J.A., and Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N. Engl. J. Med. 327 (1992) 765-771
44. Maydell B.V., Wyllie E., Akhtar N., Kotagal P., Powaski K., Cook K., Weinstock A., and Rothner A.D. Efficacy of the ketogenic diet in focal versus generalized seizures. Pediatr. Neurol. 25 (2001) 208-212
45. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., and Dietz W.H. The disease burden associated with overweight and obesity. JAMA 282 (1999) 1523-1529
46. Nabe K., Fujimoto S., Shimodahira M., Kominato R., Nishi Y., Funakoshi S., Mukai E., Yamada Y., Seino Y., and Inagaki N. Diphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets. Endocrinology 147 (2006) 2717-2727
47. Nelson T.L., Palmer R.F., and Pedersen N.L. The metabolic syndrome mediates the relationship between cynical hostility and cardiovascular disease. Exp. Aging Res. 30 (2004) 163-177
48. Nikolaos T., Stylianos G., Chryssoula N., Irini P., Christos M., Dimitrios T., Konstantinos P., and Antonis T. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med. Sci. Monit. 10 (2004) MT50-MT52
49. Novak G.P., Maytal J., Alshansky A., Eviatar L., Sy-Kho R., and Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. J. Child Neurol. 14 (1999) 490-495
50. Ozawa H., Azuma E., Shindo K., Higashigawa M., Mukouhara R., and Komada Y. Transient renal tubular acidosis in a neonate following transplacental acetazolamide. Eur. J. Pediatr. 160 (2001) 321-322
51. Penumalee S., Kissner P.Z., and Migdal S.D. Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient. Am. J. Kidney Dis. 42 (2003) E3-E5
52. Philippi H., Boor R., and Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 43 (2002) 744-747
53. Pita-Calandre E., Rodriguez-Lopez C.M., Cano M.D., and Pena-Bernal M. [Serum lipids. lipoproteins, and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid, or phenytoin]. Rev. Neurol. 27 (1998) 785-789
54. Prabhakaran D., and Anand S.S. The metabolic syndrome: An emerging risk state for cardiovascular disease. Vasc. Med. 9 (2004) 55-68
55. Pylvanen V., Pakarinen A., Knip M., and Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 8 (2006) 643-648
56. Richens A., Davidson D.L., Cartlidge N.E., and Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J. Neurol. Neurosurg. Psychiatry 57 (1994) 682-687
57. Sheth R.D. Adolescent issues in epilepsy. J. Child Neurol. 17 Suppl. 2 (2002) S23-S27
58. Sonmez F.M., Demir E., Orem A., Yildirmis S., Orhan F., Aslan A., and Topbas M. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J. Child Neurol. 21 (2006) 70-74
59. Tan H., Orbak Z., Kantarci M., Kocak N., and Karaca L. Valproate-induced insulin resistance in prepubertal girls with epilepsy. J. Pediatr. Endocrinol. Metab. 18 (2005) 985-989
60. Thearle M., and Aronne L.J. Obesity and pharmacologic therapy. Endocrinol. Metab. Clin. North Am. 32 (2003) 1005-1024
61. Verrotti A., Greco R., Latini G., and Chiarelli F. Endocrine and metabolic changes in epileptic patients receiving valproic acid. J. Pediatr. Endocrinol. Metab. 18 (2005) 423-430
62. Voudris K.A., Attilakos A., Katsarou E., Drakatos A., Dimou S., Mastroyianni S., Skardoutsou A., Prassouli A., and Garoufi A. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res. 70 (2006) 211-217
63. Willett W.C., Dietz W.H., and Colditz G.A. Guidelines for healthy weight. N. Engl. J. Med. 341 (1999) 427-434
64. Yilmaz E., Dosan Y., Gurgoze M.K., and Gungor S. Serum lipid changes during anticonvulsive treatment serum lipids in epileptic children. Acta Neurol. Belg. 101 (2001) 217-220